Unit

UNIT 13B.3 High-Throughput Screening of Viral Entry Inhibitors Using Pseudotyped Virus

  1. Arnab Basu,
  2. Debra M. Mills,
  3. Terry L. Bowlin

Published Online: 1 DEC 2010

DOI: 10.1002/0471141755.ph13b03s51

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Basu, A., Mills, D. M. and Bowlin, T. L. 2010. High-Throughput Screening of Viral Entry Inhibitors Using Pseudotyped Virus. Current Protocols in Pharmacology. 51:13B.3.1–13B.3.17.

Author Information

  1. Microbiotix, Worcester, Massachusetts

Publication History

  1. Published Online: 1 DEC 2010
  2. Published Print: DEC 2010

Abstract

Virus entry into a host cell is an attractive target for therapy because propagation of virus can be blocked at an early stage, minimizing chances for the virus to acquire drug resistance. Anti-infective drug discovery for BSL-4 viruses like Ebola or Lassa hemorrhagic fever virus presents challenges due to the requirement for a BSL-4 laboratory containment facility. Pseudotyped viruses provide a surrogate model in which the native envelope glycoprotein of a BSL-2 level virus (e.g., vesicular stomatitis virus) is replaced with envelope glycoprotein of a foreign BSL-4 virus (e.g., Ebola virus). Because the envelope glycoprotein determines interaction of virus with its cellular receptors, pseudotyped viruses can mimic the viral entry process of the original virus. Moreover, they are competent for only a single cycle of infection, and therefore can be used in BSL-2 facilities. Pseudotyped viruses have been used in high-throughput screening of entry inhibitors for a number of BSL-4 level viruses. This unit includes protocols for preparing pseudotyped viruses using lentiviral vectors and use of pseudotyped viruses for high-throughput screening of viral entry inhibitors.Curr. Protoc. Pharmacol. 51:13B.3.1-13B.3.17. © 2010 by John Wiley & Sons, Inc.

Keywords:

  • pseudotyped virus;
  • lentiviral vectors;
  • high-throughput screen